Trulieve Q2 Beat, but TRLV Still Fell 3%: Cash Flow Beat the Narrative

Trulieve Q2 beat estimates, but the stock still sold off

The setup was awkward, but it was still informative. Trulieve's Q2 ended with $271 million in revenue, a 37.5% adjusted EPS beat, and a roughly 3% post-earnings drop. In a cleaner setup, that kind of report might have been bought. Here, it was not.

This was Trulieve's first earnings test after its June 10 NYSE listing, immediately following the June 3 deconsolidation of Harvest. Bulls can read that as a milestone for a more transparent, medical-only operating story. Bears can argue the quarter still blended legacy operations until early June, so the headline numbers were not a perfectly clean before-and-after picture.

That tension helps explain the split reaction. The bullish read is that the medical-only business still has margin and cash-generation strength, with 60% gross margin and $53 million of cash flow from operations in the quarter. The bearish read is that GAAP still showed a $406 million net loss, and the market also reacted to reduced full-year cash flow guidance.

Why the Q2 loss obscures the cash story

The key Q2 issue is not just the loss. It is how much the loss reflects restructuring accounting rather than day-to-day operating weakness.

The deconsolidation charge complicates GAAP

Trulieve said Q2 included both Trulieve and Harvest operations until the deconsolidation of Harvest on June 3, 2026, and that a $407 million impact from the Harvest deconsolidation and equity investment was embedded in the quarter's GAAP result. That makes the reported net loss harder to read as a pure operating scorecard.

The cleaner contrast is right there in the non-GAAP line: adjusted net income was $20 million, or $0.11 per share. That does not erase the need for context-the quarter still mixed legacy operations before early June-but it does suggest the loss was driven heavily by a restructuring event, not solely by a collapse in demand or store performance.

First-half cash flow is the stronger signal

A better way to judge the quarter is to look beyond June alone. For the first half of 2026, Trulieve generated $109 million of cash flow from operations and $74 million of free cash flow. Those figures suggest the business was still producing cash while the reporting structure and capital setup were being reorganized.

Revenue quality also matters in cannabis. Trulieve said 94% of revenue came from retail sales, which suggests demand was coming from end customers rather than being distorted by wholesale mix. Combined with 60% gross margin, that supports the view that the core retail operation remained healthy.

What matters for the next quarter

The main post-earnings objection is not the Q2 loss by itself. It is the concern around reduced full-year cash flow guidance. That is a fair focus, because strong Q2 cash flow matters less if the second half weakens materially.

What investors should watch next

• Does H2 keep cash flow close to the first-half pace?
• Is the guidance reduction mostly timing related to the restructuring, or a sign of weaker demand?
• Can management show the medical-only model holds up more cleanly in future quarters without Harvest muddying the read?